Drug Profile
Research programme: anti-CD27 antibodies - Celldex Therapeutics Inc
Alternative Names: Anti-CD27 antibodiesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Celldex Therapeutics Inc
- Class Monoclonal antibodies
- Mechanism of Action CD27 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer